This is a working overview of tissue repair, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Typical storage | Minus 20 C or below | Lyophilized powder, protected from light |
| Solubility class | Freely soluble in water | Also dissolves in normal saline |
| Identity method | Mass spectrometry | Measured mass compared with calculated value |
| Purity method | Reverse-phase HPLC | Reported as area percentage of main peak |
| Common counterion | Acetate | Salt form varies by supplier and batch |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
== Reactions == Superheated water, along with supercritical water, has been used to oxidise hazardous material in the wet oxidation process. Organic compounds are rapidly oxidised without the production of toxic materials sometimes produced by combustion. However, when the oxygen levels are lower, organic compounds can be quite stable in superheated water. As the concentration of hydronium (H3O+) and hydroxide (OH−) ions are 100 times larger than in water at 25 °C, superheated water can act as a stronger acid and a stronger base, and many different types of reaction can be carried out. An example of a selective reaction is oxidation of ethylbenzene to acetophenone, with no evidence of formation of phenylethanoic acid, or of pyrolysis products. Several different types of reaction in which water was behaving as reactant, catalyst and solvent were described by Katritzky et al. Triglycerides can be hydrolysed to free fatty acids and glycerol by superheated water at 275 °C, which can be the first in a two-stage process to make biodiesel.
=== Synthetic === The availability of synthetic toxin has allowed scientists to further explore the biological activity of the toxin, resulting in the observation that d-ACTX-Ar1a causes repetitive firing and prolongation of the action potential. These actions underlie the clinical symptoms seen following envenomation and further contribute to the understanding of the molecular basis for activity of this potent neurotoxin on voltage-gated sodium channels. Under voltage-clamp conditions in dorsal root ganglion (DRG) neurons it was found that the effects of the synthetic toxin on sodium currents were not significantly different from those previously reported for the native toxin. Neither native nor synthetic d-ACTX-Ar1a had any effect on TTX-resistant sodium currents, but both exerted a potent selective modulation of TTX-sensitive sodium currents consistent with actions on neurotoxin receptor site-3. This includes a slowing of the sodium-channel inactivation, a hyperpolarizing shift in the voltage-dependence of activation and a hyperpolarizing shift in the steady-state sodium-channel inactivation. d-ACTX-Ar1a causes a prolongation of action potential duration, accompanied by spontaneous repetitive firing, but does not depolarize the resting membrane potential. Effects on the autonomic nervous system, including vomiting, profuse sweating, salivation, lachrymation, marked hypertension followed by hypotension, together with effect on the somatic nervous system to cause muscle fasciculation and dyspnea (shortness of breath) are presumably due to excessive transmitter release.
{\displaystyle (\mathbf {g} _{i},\nabla p)=-{\bigl (}\mathbf {g} _{i},\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} _{j}{\bigr )}-\nu \left(\nabla \mathbf {g} _{i}:\nabla \mathbf {u} _{j}\right)+\left(\mathbf {g} _{i},\mathbf {f} ^{I}\right)}
Successful international boycotts of Australian Merino wool in the early 2000s set those invested in Australian sheep rearing on the hunt for alternatives. The publicity generated intense interest in finding a replacement for mulesing that domestic and international consumers would accept. An adaptation of the freeze branding process was hit upon in the 2010s. The new technique was quickly christened steining after its designer, John Steinfort, an Australian veterinary scientist. In 2019 Australian Wool Network (AWN), a private corporation servicing the Australian wool industry, provided Steinfort funding to commercialize the technique. During steining hollow cupronickel clamping jaws about 4 inches (10 cm) long are used to pinch up rolls of skin beneath the tail and near the anus of a lamb. No shaving is required in this application of freeze branding. Once sufficient skin is in the clamps liquid nitrogen is pumped through the jaws and onto the pinched skin. This rapidly freezes the lamb's skin as it drips out of the jaws and through the animal's fleece. The goal is to achieve a level of cellular injury that prevents future hair growth but not so much that a 3rd-degree cold burn is created. Pinching the skin is thought to mitigate the degree of cold burn by removing it somewhat from the muscles and connective tissue beneath. The treated skin goes through the same stages of healing seen in the long method of freeze-branding larger livestock, concluding with permanent hairlessness.
Sources: en.wikipedia.org
=== Continental Europe === A translation of the Oxford team's 1941 report reached Germany via Sweden the following year. On 6 December 1943, the Reich Health Ministry ordered the medical community to conduct research into penicillin and other antibiotics. Three vials of penicillin captured by the Afrika Korps reached Germany in 1943 and one was sent to Heinz Öppinger at Hoechst in Frankfurt, who began conducting experiments with moulds. Penicillin was produced there in 300-litre batches, and Öppinger developed a rotating drum for a deep-tank fermentation process. Research was also carried out by Schering in Berlin using a sample of Fleming's mould, which they failed to cultivate; their efforts to determine the chemical structure of penicillin were also unsuccessful. Maria Brommelhues at IG Farben's Bacteriological Laboratory in Elberfeld catalogued different species of penicillin. Hitler's personal physician, Theodor Morell, treated Hitler with penicillin for injuries sustained in the 20 July 1944 assassination attempt. Information about penicillin research in Germany was gathered by the Manhattan Project's Alsos Mission and forwarded to Florey in the UK. Much of Germany's penicillin came from Czechoslovakia, where research was carried out at Charles University in Prague and the Fragner Pharmaceutical Company by a team that included chemist Karel Wiesner. Work was also conducted in secret in France and at the Delft University of Technology in the Netherlands.
Little Caesars sold its first franchise in 1962 and, by 1987, had restaurants in all 50 states. Throughout the 1990s and early 2000s, Little Caesars were commonly found in Kmart stores, more specifically in Big Kmarts and Super Kmart. Little Caesars pizza was also included in many older, remodeled Kmart locations. The first Kmarts with Little Caesars were built in Garden City, Michigan. After Kmart's bankruptcy issues, many Kmarts replaced the Little Caesars restaurants with their own branded "K-Cafe". However, as of 2021, two Little Caesars/Kmart locations remain– in Guam and USVI. Between 2008 and 2015, Little Caesars was the fastest-growing pizza chain in the United States. As of 2017, the company had 5,463 locations including U.S. and international units. The estimated total investment necessary to begin the operation of a Little Caesars Franchise ranges from $378,700 to $1,695,500.
At Australia's federation in 1901, the Constitution section 51(xxxv) empowered the making of "laws for the peace, order, and good government of the Commonwealth with respect to... conciliation and arbitration for the prevention and settlement of industrial disputes extending beyond the limits of any one state". This was used to pass the Commonwealth Conciliation and Arbitration Act 1904 where a "dispute" would trigger federal jurisdiction between trade unions and employers, and this was meant to make strikes illegal or unnecessary, although in fact strikes remained "not uncommon". The Commonwealth Court of Conciliation and Arbitration (CCCA) could hear disputes, and make "awards" for fair wages and conditions across an industry if there was no agreement reached, or regulate any "industrial matters". With favourable governments in power, some courts were progressive, and in the landmark Harvester case the CCCA determined that the employer, Hugh Victor McKay that made harvesting machinery, was required to pay "fair and reasonable wages", or pay an excise tax on exports, under the Excise Tariff Act 1906. What was "fair and reasonable", said Higgins J depended on "the normal needs of an average employee, regarded as a human being in a civilised community", and this was to be found by imagining a hypothetical collective agreement, not individual bargaining with the "usual, but unequal, contest, the "higgling of the market" for labour, with the pressure for bread on one side and the pressure for profits on the other".
=== Screenwriting === For her screenplay Look for Water, which she co-wrote with Dominic Mah, she was invited to the Sundance Screenwriters' Lab in June 2008. The screenplay has also received the Tribeca Film Festival L'Oreal Woman of Worth Vision Award, a Sundance CineReach grant, and a Sundance Institute Annenberg Feature Film Fellowship Grant.
== Radionuclides == When radionuclides are used pharmacologically, for example in radiation therapy, they are eliminated through a combination of radioactive decay and biological excretion. An effective half-life of the drug will involve a decay constant that represents the sum of the biological and physical decay constants, as in the formula:
Sources: en.wikipedia.org
studied oils from the marine-derived Upper Cretaceous Second White Speckled Shale and found strong depleted signal around −180‰ in C12-C18. The low δD of this marine samples was explained by the discharge of a large high latitude river. Schimmelmann et al. found that the δD of the oil sampled from coaly facies of the Crayfish group reaches down to −230‰ where as those sampled from algal facies of the same group are around −100‰. Such huge variation is hard to explain by any other causes than Australia splitting from Antarctica in late Cretaceous. Another special case reported by Xiong et al. studied Ordovician carbonates from Bohai Bay Basin. They found big differences between δD of n-alkanes, reflecting that the original signal is preserved rather than being homogenized. The result is not obvious as the sample is very mature (inferred vitrinite reflectance R0 up to 2.3). Thus this is strong evidence that carbonate systems have much lower catalytic efficiency of hydrogen exchange on hydrocarbons. Strong enrichment (~40‰) in odd carbon numbered alkanes to even carbon numbered alkanes is also found in some subset of samples and the reason is unclear at this point. This odd-even effect is also observed in immature clastic sediments.
Plant foods lose less during processing, as they contain pyridoxine, which is more stable than the pyridoxal or pyridoxamine forms found in animal-sourced foods. For example, milk can lose 30–70% of its vitamin B6 content when dried. The vitamin is found in the germ and aleurone layer of grains, so there is more in grains from which these layers have not been removed, for example more in whole wheat bread than in white wheat bread, and more in brown rice than in white rice. Most values shown in the table are rounded to nearest tenth of a milligram:
At absolute zero temperature, the gas possesses zero energy and hence the molecules restrict motion. Gay-Lussac had no experience of liquid air (first prepared in 1877), although he appears to have believed (as did Dalton) that the "permanent gases" such as air and hydrogen could be liquified. Gay-Lussac had also worked with the vapours of volatile liquids in demonstrating Charles's law, and was aware that the law does not apply just above the boiling point of the liquid:
=== Slaughter by the consumer === Insects may also be sold live for food purposes, and thus effectively slaughtered by the end human consumer prior to eating. Some "how to" guides for eating insects make no mention of freezing or other euthanasia methods. For example, Miles Olson's recommendations include:
Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial). (ICH E6) Sponsor
Sources: en.wikipedia.org
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.
Cold storage at minus twenty degrees Celsius or below is the common recommendation for the lyophilized powder, together with protection from light and moisture. Dissolved material is generally treated as less stable and is handled cold with short working windows.
A useful certificate lists the analytical method used, the measured purity, the mass determined by spectrometry, and the storage conditions. Independent verification from a second laboratory is sometimes requested, since supplier-issued documents are not always produced in the same facility as the material.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.